INBRIJA

• druglevodopa31 co-mentions · 8 sources
• tagApproval22 co-mentions · 6 sources
• druglevodopa CR21 co-mentions · 8 sources
• drugSINEMET CR12 co-mentions · 3 sources
• drugentacapone10 co-mentions · 2 sources
• companyRising Pharma Holdings Inc3 co-mentions · 1 sources
• tagRecall3 co-mentions · 1 sources
• drug(carbidopa + levodopa)1 co-mentions · 1 sources

Trials studying INBRIJA

• phase3A Study to Evaluate the Efficacy and Safety of HRG2010 in Parkinson's Disease With Motor Fluctuationscompletedn=165
• phase1A Study to Assess Effect of Dosing Intervals on Multiple-Dose Pharmacokinetics of WD-1603 Taken Before Meals in Healthy Participantsrecruitingn=12
• phase1A Pilot Comparative Bioavailability Study of Levodopa Administered Via Levodopa Cyclops® Relative to INBRIJA®completedn=26
• —Observational Small Intestine and Blood Fingerprint (SmIle) Study in Parkinson's Diseaseactive not recruitingn=100
• phase2Pharmacokinetics,Pharmacodynamics,Efficacy and Safety of HRG2010 in Parkinson's Disease Patients With Motor Fluctuationscompletedn=61
• phase1A Safety, Tolerability, and Plasma Concentration Study of Levodopa/Carbidopa Subcutaneous Solution (ND0612) in Parkinson's Disease (PD) Patientscompletedn=8
• phase2A Phase 2a Study Followed to Evaluate the Safety, Tolerability and Levodopa Pharmacokinetics in Levodopa-treated Parkinson's Disease Patients Receiving ND0612completedn=30
• phase2A Study to Evaluate SAGE-217 in Participants With Parkinson's Diseasecompletedn=29